ASTRAVEUS

Astraveus is founded on July 7, 2016 at the Saint-Louis Hospital in Paris, based on Jérémie's thesis work. The Company starts with research activities funded by its team members, BPI France and the European Commission. After 6 years, twelve passionate people deliver key technology building blocks that result in patents and the assembly of a prototype, demonstrating the viability of Astraveus benchtop cell therapy concept. This convinces AdBio Partners, Bpifrance Large Venture, Merck (M Ventures) and J&J (JJDC) to invest €16.5M in the Company and the French state to grant €10.4M as part of the France 2030 initiative. Astraveus is currently focused on the development of Lakhesys™ benchtop cell factory and its commercialization.

At Astraveus, we strive to enable a healthier tomorrow. We believe in the therapeutic potential of cell therapies. Through the development of our Lakhesys™ benchtop cell factory, we aspire to make cell therapies more accessible to patients in need. In this context, we are actively recruiting along multiple dimensions of our activity, from product inception to market launch.

Astraveus' values are reflected in the day-to-day work of the team and are shared by all. During the recruitment process, an entire interview is dedicated to cultural fit, which is just as important to us as technical fit. Our values are kindness, excellence, transparency and lightness.